NASDAQ: NVAXNovavax Revenue
Novavax revenue was $682.16M for the trailing 12 months ending Dec 31, 2024, with N/A growth year over year. Quarterly revenue for the quarter (Q4 2024) ending on Dec 31, 2024 was $88.3M, up 4.5% from last quarter. For the last reported fiscal year 2024 ending Dec 31, 2024, NVAX annual revenue was $682.2M, with -30.7% growth year-over-year.
NVAX past revenue growth
How has NVAX's revenue growth performed historically?
Company
-30.65%
Industry
505.6%
Market
20.84%
NVAX's revenue has grown faster... subscribe to Premium to read more.
Revenue Growth vs Industry Performance
NVAX's revenue has grown faster... subscribe to Premium to read more.
Revenue Growth vs Market Performance
NVAX's revenue growth is slowing... subscribe to Premium to read more.
Accelerating Revenue Growth Performance
NVAX revenue history
Current Revenue
$682.2M
Current Earnings
-$187.5M
Current Profit Margin
-27.5%
Be the first to know when NVAX announces revenue.
NVAX Revenue History By Year
| NVAX Yearly Revenue | NVAX Revenue | NVAX Change | NVAX Revenue Growth |
|---|---|---|---|
| 2024-12-31 | $682.16M | -$301.54M | -30.65% |
| 2023-12-31 | $983.71M | -$998.17M | -50.36% |
| 2022-12-31 | $1.98B | $835.58M | +72.89% |
| 2021-12-31 | $1.15B | $670.69M | +141.02% |
| 2020-12-31 | $475.60M | $456.94M | +2,448.48% |
| 2019-12-31 | $18.66M | -$15.63M | -45.57% |
| 2018-12-31 | $34.29M | $3.11M | +9.98% |
| 2017-12-31 | $31.18M | $15.82M | +103.06% |
| 2016-12-31 | $15.35M | -$20.90M | -57.65% |
| 2015-12-31 | $36.25M | $5.59M | +18.24% |
| 2014-12-31 | $30.66M | $9.74M | +46.59% |
| 2013-12-31 | $20.92M | -$1.16M | -5.26% |
| 2012-12-31 | $22.08M | $7.39M | +50.30% |
| 2011-12-31 | $14.69M | $14.35M | +4,182.22% |
| 2010-12-31 | $343.00k | $18.00k | +5.54% |
| 2009-12-31 | $325.00k | -$739.00k | -69.45% |
| 2008-12-31 | $1.06M | -$449.00k | -29.68% |
| 2007-12-31 | $1.51M | -$225.00k | -12.95% |
| 2006-12-31 | $1.74M | -$3.61M | -67.47% |
| 2005-12-31 | $5.34M | -$2.92M | -35.31% |
| 2004-12-31 | $8.26M | -$3.53M | -29.91% |
| 2003-12-31 | $11.79M | -$3.22M | -21.46% |
| 2002-12-31 | $15.01M | -$9.06M | -37.65% |
| 2001-12-31 | $24.07M | $21.59M | +872.36% |
| 2000-12-31 | $2.48M | $1.29M | +109.57% |
| 1999-12-31 | $1.18M | $500.00k | +73.42% |
| 1998-12-31 | $681.00k | $161.00k | +30.96% |
| 1997-12-31 | $520.00k | $464.00k | +828.57% |
| 1996-12-31 | $56.00k | -$212.00k | -79.10% |
| 1995-12-31 | $268.00k | -$416.88k | -60.87% |
| 1994-12-31 | $684.88k | N/A | N/A |
Novavax Revenue FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.